Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New Biomarker Panel Could Accelerate Autism Diagnoses

By LabMedica International staff writers
Posted on 17 Sep 2018
Autism Spectrum Disorder is characterized by core symptoms of altered social communication and repetitive behaviors or circumscribed interests and has a prevalence of 1:59 children in the USA. Affected individuals vary enormously in the severity of their autistic characteristics as well as in the occurrence of many co-morbid conditions.

No biomarker tests for autism spectrum disorder (ASD) currently exist. Children are diagnosed based on their altered behaviors, which may not become evident until children are two to four years old. Families often must wait over a year or more for an appointment with a specialist, delaying diagnosis even further.

A team of scientists working with those at the University of California Davis (Davis, CA, USA) recruited children, ages 18 to 48 months, from eight centers across the USA. Each participant underwent physical, neurological and behavioral examinations. Metadata was obtained about the children's birth, developmental, medical and immunization histories, dietary supplements and medications. Parents’ medical histories were also obtained. Blood was collected from subjects after at least a 12 hour fast by venipuncture into 6 mL sodium heparin tubes on wet ice.

The investigators used the Waters AccQTag Ultra kit, which employs derivatization of amine moieties with 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate and was employed for all samples prior to multiple reaction monitoring (MRM) on a liquid chromatography (LC) mass spectrometry (MS) system consisting of an Agilent 1290 ultra-high performance liquid chromatograph (UHPLC) coupled to an Agilent G6490 Triple Quadrupole Mass Spectrometer.

The team compared blood metabolites, specifically, amino acids, in 516 children with ASD and 164 children showing typical development. They found that 17% of the ASD children had unique concentrations of specific amino acids, known as metabotypes, in their blood. Though a 17% subgroup may seem small, it is actually quite significant. The combination of glutamine, glycine, and ornithine Amino Acid Dysregulation Metabotypes (AADMs) identified a dysregulation in amino acid/ branch chain amino acid (AA/BCAA) metabolism that is present in 16.7% of the ASD subjects and is detectable with a specificity of 96.3% and a positive predictive value (PPV) of 93.5%.

The author demonstrates one approach to analyzing the metabolism of ASD to successfully identify reproducible metabotypes. Analysis of the study samples is ongoing and there will be additional metabotypes, which will be diagnostic for subsets of children with ASD. Stratifying ASD based on metabotypes offers an opportunity to identify efficacious interventions within metabotypes that can lead to more precise and individualized treatment.

David G. Amaral, PhD, a professor of psychiatry and lead investigator of the study, said, “With this panel of alterations in amino acid metabolism, we can detect about 17% of kids with ASD. This is the first of hopefully many panels that will identify other subsets of kids with autism.” The study was published on September 6, 2018, in the journal Biological Psychiatry.

Related Links:
University of California Davis


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Coagulation Analyzer
CS-2400
New
Uric Acid and Blood Glucose Meter
URIT-10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.